NYMX - NYMOX PHARMACEUTICAL CORP

0   0%

Share volume: 0
Last Updated:
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: 0.03%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 20%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
N/A
P/E Ratio 
N/A
DAY RANGE
N/A - N/A
EPS 
N/A
52 WEEK RANGE
N/A - N/A
52 WEEK CHANGE
N/A
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Paul Averback
Region: US
Website: nymox.com
Employees: 3
IPO year: 2023
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Nymox Pharmaceutical Corporation engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Recent news
loading